Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Global Select Market

0.61USD
8 Dec 2016
Change (% chg)

$0.01 (+1.76%)
Prev Close
$0.60
Open
$0.61
Day's High
$0.62
Day's Low
$0.59
Volume
33,364
Avg. Vol
33,007
52-wk High
$1.41
52-wk Low
$0.57

AVEO.OQ

Chart for AVEO.OQ

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $46.66
Shares Outstanding(Mil.): 75.86
Dividend: --
Yield (%): --

Financials

  AVEO.OQ Industry Sector
P/E (TTM): -- 41.20 30.65
EPS (TTM): -0.44 -- --
ROI: -90.03 -0.59 15.23
ROE: -203.34 -1.31 16.56

BRIEF-Aveo Pharmaceuticals says Eusa Pharma submits its responses to EMA day 120 list of questions

* Says its development partner, Eusa Pharma, submitted its responses to European Medicines Agency (EMA) day 120 list of questions

Nov 28 2016

BRIEF-Aveo Oncology Q3 loss per share $0.07

* Says believe that $30.8 million in cash resources could allow to fund planned operations into Q4 of 2017

Nov 04 2016

BRIEF-Aveo Oncology announces proposed settlement and settlement hearing in stockholder litigation

* Aveo Oncology announces proposed settlement and settlement hearing in 2014 stockholder litigation

Sep 30 2016

BRIEF-Aveo Pharmaceuticals announced discontinuation of focal study

* Announced discontinuation of focal study, a phase 2, placebo controlled clinical study, evaluating ficlatuzumab

Sep 12 2016

BRIEF-Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma

* Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo (nivolumab) in advanced renal cell carcinoma

Aug 15 2016

BRIEF-Aveo Oncology Q2 loss per share $0.13

* Aveo oncology reports second quarter 2016 financial results and provides business update

Aug 04 2016

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,401 +11.00
Eisai Co., Ltd (4523.T) ¥6,388 +113.00
Pfizer Inc. (PFE.N) $30.94 -0.25
Novartis AG (NOVN.S) CHF68.50 -0.25
Roche Holding Ltd. (ROG.S) CHF220.40 -0.80
Roche Holding Ltd. (RO.S) CHF226.10 +0.90
Bayer AG (BAYGn.DE) €93.17 +3.07
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.08 -0.02
AstraZeneca plc (AZN.L) 4,116.00p +109.00

Earnings vs. Estimates